CAS: 76003-29-7; 1-Boc-3-Oxopiperazine

相似化合物

13754-41-1 34770-60-0 5625-67-2

上下游产品

CAS号5625-67-2 2-哌嗪酮 | CAS号24424-99-5 二碳酸二叔丁酯 | CAS号105-39-5 氯乙酸乙酯 | CAS号107-06-2 1,2-二氯乙烷 | CAS号179051-25-3 1-(2-naphthylme... | CAS号109384-26-1 4-甲基-3-氧代哌嗪-1-羧酸叔丁酯 | CAS号345311-03-7 7-B°C-5,6,7,8-四... | CAS号194350-95-3 1-乙基-4-(叔丁基氧基羰基... | CAS号194351-12-7 1-(2'-FLUORO)ET... | CAS号549506-47-0 2-(4-(叔丁氧基羰基)-2... | CAS号76003-30-0 2-甲基-3-氧代哌嗪-1-羧酸叔丁酯 | CAS号1215852-11-1 7-B°C-5,6,7,8-四... | CAS号78551-60-7 4-苄基-3-氧代哌嗪-1-甲酸叔丁酯

二碳酸二叔丁酯 以 乙酸乙酯,乙腈 作为反应溶剂,化学反应生成 3-氧代-1-哌嗪羧酸叔丁酯
参考文献:N-Acylsulfonamide Apoptosis Promoters
标题:N-Acylsulfonamide Apoptosis Promoters
摘要:N-苯甲酰芳基磺胺酰胺具有以下化学式,是bcl-X1抑制剂,有助于促进细胞凋亡.还公开了bcl-X1抑制组合物和在哺乳动物中促进细胞凋亡的方法.

专利信息

专利号:US-9475814-B2
优先权日:2011-10-03
标题:Chiral N-acyl-5,6,7(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines as selective NK-3 receptor antagonists, pharmaceutical composition, methods for use in NK-3 receptor mediated disorders and chiral synthesis thereof
发明人：HOVEYDA HAMID R; DUTHEUIL GUILLAUME; FRASER GRAEME L; ROY MARIE-ODILE; EL BOUSMAQUI MOHAMED; BATT FREDERIC
权利人:EUROSCREEN SA
摘要:The present invention relates to novel compounds of Formula I and their use in therapeutic treatments. The invention further relates to a novel chiral synthesis of 5,6,7,(8-substituted)-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazines using N-sp3 protective groups. The invention also provides intermediates for use in the synthesis of compounds of Formula I.

专利号:US-2009137577-A1
优先权日:2007-06-29
标 题 :Heterocyclic compounds
发明人：DUPLANTIER ALLEN J; EFREMOV IVAN; ZHANG LEI; MAKLAD NOHA S; O'SULLIVAN THERESA
权利人:PFIZER
摘要:Compounds and pharmaceutically acceptable salts of the compounds are disclosed, wherein the compounds have the structure of Formula I n n n n n n n n n n as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.

专利号:US-9745253-B2
优先权日:2015-03-13
标 题 :Alpha-cinnamide compounds and compositions as HDAC8 inhibitors
发明人：BAIR KENNETH W; Barczak Nicholas; HAN BINGSONG; LANCIA JR DAVID R; LIU CUIXIAN; MARTIN MATTHEW W; NG PUI YEE; Rudnitskaya Aleksandra; THOMASON JENNIFER R; ZABLOCKI MARY MARGARET; ZHENG XIAOZHANG
权利人:FORMA THERAPEUTICS INC
摘要:The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9187522-B2
优先权日:2011-12-12
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC
摘要:The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.